UPDATE: Goldman Sachs Lowers PT on United Therapeutics to $52

Goldman Sachs is out with its report today on United Therapeutics UTHR, lowering its PT to $52 from $82. In its report, Goldman Sachs writes, "We are reducing our 12-month price target to $52 from $82, as we now exclude oral Remodulin from our estimates and valuation and we have also lowered our M&A ranking to '3' from '1.' Our 12-month price target $52 is derived from a 50%/50% blend of our SOTP ($54) and DCF ($50) value." Goldman Sachs maintains Buy on UTHR. Shares of UTHR closed Wednesday at $39.91, down 18.15% from Tuesday's close.